Literature DB >> 2659684

Androgen influence on exocrine pancreatic cancer.

A Andrén-Sandberg1.   

Abstract

Since the discovery of the first gastrointestinal hormones it has been intriguing to think that these defined chemical messengers may also influence the growth of tumors. Today, treatment with sex-hormones is well documented--and used in clinical practice--in prostatic (1,2), breast (3), endometrial, and ovarian carcinoma (4). Hormonal therapy (progesterone) has also been tried with some success in renal carcinoma (5,6). Nevertheless, cancers of the gastrointestinal tract--colorectal, liver, stomach, and pancreatic, carcinoma, which constitute 25 percent of all malignancies in Scandinavia--are only treated by other means, mainly surgery, although there is substantial evidence today that these tumors can also be influenced by hormones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659684     DOI: 10.1007/bf02938472

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  24 in total

1.  Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas.

Authors:  D Gonzalez-Barcena; N E Rangel-Garcia; P L Perez-Sanchez; C Gutierrez-Damperio; F Garcia-Carrasco; A M Comaru-Schally; A V Schally
Journal:  Lancet       Date:  1986-07-19       Impact factor: 79.321

2.  Hormonal therapy for prostate cancer.

Authors:  F M Torti
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

3.  Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

4.  Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.

Authors:  J I Paz-Bouza; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

5.  Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats.

Authors:  E F Lhoste; B D Roebuck; T Brinck-Johnsen; D S Longnecker
Journal:  Carcinogenesis       Date:  1987-05       Impact factor: 4.944

6.  Somatostatin enhances binding of [3H]estradiol to a cytosolic protein in rat pancreas. Possible role of oligopeptide coligands in secretion.

Authors:  P Band; S B Richardson; A M Boctor; A Grossman
Journal:  J Biol Chem       Date:  1983-06-25       Impact factor: 5.157

7.  Effect of orchiectomy and testosterone on the early stages of azaserine-induced pancreatic carcinogenesis in the rat.

Authors:  E F Lhoste; B D Roebuck; J E Stern; D S Longnecker
Journal:  Pancreas       Date:  1987       Impact factor: 3.327

8.  Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy.

Authors:  E Nakano; Y Tada; H Fujioka; M Matsuda; M Osafune; T Kotake; B Sato; M Takaha; T Sonoda
Journal:  J Urol       Date:  1984-08       Impact factor: 7.450

9.  Requirement for an accessory factor for binding of [3H]estradiol to protein in the cytosol fraction of rat pancreas.

Authors:  A M Boctor; P Band; A Grossman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

10.  Low serum testosterone concentrations in patients with carcinoma of the pancreas.

Authors:  B Greenway; M J Iqbal; P J Johnson; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-08
View more
  7 in total

Review 1.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

2.  Effects of sex steroid hormones on pancreatic cancer in the rat.

Authors:  D S Longnecker; C Sumi
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

Review 3.  Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.

Authors:  B Fazeny; M Baur; M Prohaska; M Hudec; M Kremnitzer; S Meryn; H Huber; T Grunt; A Tuchmann; C Dittrich
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 4.  Hormonal therapy of pancreatic carcinoma. Rationale and perspectives.

Authors:  D Perilli; C Mansi; V Savarino; G Celle
Journal:  Int J Pancreatol       Date:  1993-06

Review 5.  Hormones and pancreatic cancer.

Authors:  D S Longnecker
Journal:  Int J Pancreatol       Date:  1991

6.  Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.

Authors:  Sanjay Singh Negi; Anil Agarwal; Adarsh Chaudhary
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

7.  Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.

Authors:  P A Philip; J Carmichael; K Tonkin; P K Buamah; J Britton; M Dowsett; A L Harris
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.